VANCOUVER, British Columbia, Nov. 1, 2010 (GLOBE NEWSWIRE) -- Immune Network Ltd. (Pink Sheets:IMMFF), a company in the business of discovery and development of immune-based therapies, today announced that patient enrollment will be completed next week for the company's future partner Immunitor's Phase 2b imm01 trial of V5 immunotherapy in 120 patients with tuberculosis. V5 is an orally delivered once-daily tablet that in combination with standard TB drugs had so far produced clearance of Mycobacterium tuberculosis in sputum smear of about 95% of treated TB patients within one month.
